Arrowhead Pharmaceuticals Inc.
ARWR
Get informed when a big investor buys or sells
+ FollowMarket Cap$11.67B
Close$
$-3.88
104.7% downside
Current Fair Value
104.7% downsideOvervalued by 104.7% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $11.67 Billion |
|---|---|
| Enterprise Value | $12.57 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.01 |
| Beta | 1.29 |
| Outstanding Shares | 143,378,000 |
Return
| Return on Equity | -68.73% |
|---|---|
| Return on Assets | -15.15% |
| Return on Invested Capital | -10.77% |
Valuation & Multiples
| P/E Ratio | -36.99 |
|---|---|
| PEG | -340.44 |
| Price to Sales | 20.71 |
| Price to Book Ratio | 27.62 |
| Enterprise Value to Revenue | 18.78 |
| Enterprise Value to EBIT | -63.83 |
| Enterprise Value to Net Income | -40 |
| Total Debt to Enterprise | 0.08 |
| Debt to Equity | 2.06 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 6, 2026
EPS Estimate
$-1.19
Average shareholder expectationRevenue Estimate
$47.89 M
Average shareholder expectationNext Earnings Call
Expected Date
November 24, 2026
EPS Estimate
$-1.59
Average shareholder expectationRevenue Estimate
$59.43 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.4359▼ 9.71% |
|---|---|
| Total Calls | 1,753,000▲ 9.52% |
| Total Puts | 764,100▼ 10.43% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 83.88%▼ 0.97% |
|---|---|
| Total Invested | $9.81B▲ 29.46% |
| Investors Holding | 522▲ 61.00% |
ESG Score
No data
About Arrowhead Pharmaceuticals Inc.
CEO: Christopher Anzalone